Literature DB >> 7955381

Six osteocalcin assays compared.

E M Díaz Diego1, R Guerrero, C de la Piedra.   

Abstract

We evaluated comparatively six commercially available osteocalcin kits: ELSA-OST-NAT IRMA (CIS), ELSA-Osteo IRMA (CIS), Osteocalcin IRMA (Nichols), OSTK-PR RIA (CIS), OSCA Test Osteocalcin RIA (Henning), and Osteocalcin RIA (Nichols). All of them presented acceptable values of variance, sensitivity, and serial dilutions. However, only the ELSA-OST-NAT, ELSA-Osteo, and OSCA Test kits had analytical recoveries near 100% for added purified human osteocalcin; the other assays showed important differences in standardization. After treating samples with antibody against amino acids 43-49 of human osteocalcin, only the ELSA-OST-NAT IRMA detected no residual osteocalcin. Stability of serum values at room temperature and at 4 degrees C is good in the ELSA-Osteo and Osteocalcin IRMAs and in the Henning RIA if serum samples are collected in special tubes available with the kit. Differences in stability and after antibody treatment can be due to the degradation of intact osteocalcin molecules in serum and to osteocalcin fragments detected by assays. Results by different assays were well correlated for samples from controls and postmenopausal osteoporotic women but not for patients with impaired renal function or Paget disease of bone, probably because of osteocalcin fragments accumulated in serum of these patients and differences in specificity of the assays.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7955381

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  6 in total

1.  Biochemical markers of bone turnover: part I: biochemistry and variability.

Authors:  Markus J Seibel
Journal:  Clin Biochem Rev       Date:  2005-11

2.  Diagnostic performance of osteocalcin measurements in patients with endogenous Cushing's syndrome.

Authors:  Zhanna E Belaya; Alexander V Iljin; Galina A Melnichenko; Alexander G Solodovnikov; Liudmila Y Rozhinskaya; Larisa K Dzeranova; Ivan I Dedov
Journal:  Bonekey Rep       Date:  2016-06-15

3.  Variable efficacy of bone remodeling biochemical markers in the management of patients with Paget's disease of bone treated with tiludronate.

Authors:  C de la Piedra; A Rapado; E M Díaz Diego; M A Díaz Martín; C Aguirre; E López Gavilanes; M Díaz Curiel
Journal:  Calcif Tissue Int       Date:  1996-08       Impact factor: 4.333

4.  Biochemical markers in the follow-up of the osteoporotic patients.

Authors:  Alessandro Terreni; Paola Pezzati
Journal:  Clin Cases Miner Bone Metab       Date:  2012-09-30

5.  Biochemical markers of bone formation in the study of postmenopausal osteoporosis.

Authors:  C Dominguez Cabrera; M Sosa Henríquez; M L Traba; E Alvarez Villafañe; C de la Piedra
Journal:  Osteoporos Int       Date:  1998       Impact factor: 4.507

Review 6.  Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club.

Authors:  P Bergmann; J-J Body; S Boonen; Y Boutsen; J-P Devogelaer; S Goemaere; J-M Kaufman; J-Y Reginster; V Gangji
Journal:  Int J Clin Pract       Date:  2009-01       Impact factor: 2.503

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.